Drug Trial Radar · NCT07364877
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
38
Planned (sponsor's estimate)
Start
Dec 28, 2025
Primary completion
Mar 19, 2026
Study completion May 18, 2026
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Safety and pharmacokinetic characteristics evaluation of DW4421 and DW4421S
Conditions
- Healthy Adult Volunteer
Interventions
DW4421Drug
DW4421 or DW4421S
DW4421SDrug
DW4421 or DW4421S
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: up to 48 hour
- AUC0-tTime frame: up to 48 hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungbuk National University Hospital
Cheongju-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.